GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (OTCPK:CASBF) » Definitions » Equity-to-Asset

CanSino Biologics (CanSino Biologics) Equity-to-Asset : 0.60 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CanSino Biologics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $709.09 Mil. CanSino Biologics's Total Assets for the quarter that ended in Mar. 2024 was $1,189.85 Mil. Therefore, CanSino Biologics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.60.

The historical rank and industry rank for CanSino Biologics's Equity-to-Asset or its related term are showing as below:

CASBF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57   Med: 0.66   Max: 0.9
Current: 0.6

During the past 8 years, the highest Equity to Asset Ratio of CanSino Biologics was 0.90. The lowest was 0.57. And the median was 0.66.

CASBF's Equity-to-Asset is ranked better than
53.36% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs CASBF: 0.60

CanSino Biologics Equity-to-Asset Historical Data

The historical data trend for CanSino Biologics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Equity-to-Asset Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.82 0.90 0.67 0.59 0.57

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.60 0.60 0.57 0.60

Competitive Comparison of CanSino Biologics's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Equity-to-Asset falls into.



CanSino Biologics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

CanSino Biologics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=738.719/1305.113
=0.57

CanSino Biologics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=709.089/1189.848
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CanSino Biologics  (OTCPK:CASBF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


CanSino Biologics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics (CanSino Biologics) Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.